These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 35015982

  • 1. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D, Bengtson LGS, Conoscenti CS, Laouri M, Shetty SS, Anderson AJ, Brown KK.
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL, Maher TM, Acciai V, Mounir B, Quaresma M, Zouad-Lejour L, Wells CD, De Loureiro L.
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D, Bengtson LGS, Conoscenti CS, Anderson AJ, Brekke L, Shetty SS, Brown KK.
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [Abstract] [Full Text] [Related]

  • 7. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 8. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [Abstract] [Full Text] [Related]

  • 9. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M, Steffens A, Anderson A, Brekke L, Grace Johnson M, Veeranki P, Olson AL.
    J Manag Care Spec Pharm; 2024 Feb 03; 30(2):163-174. PubMed ID: 38308627
    [Abstract] [Full Text] [Related]

  • 10. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI, Park H, Park S, Shin JY, Kim YH.
    BMC Pulm Med; 2023 Mar 22; 23(1):98. PubMed ID: 36949407
    [Abstract] [Full Text] [Related]

  • 11. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M, Hirvonen T, Perkonoja K, Hirsjärvi S.
    Medicina (Kaunas); 2023 Jan 31; 59(2):. PubMed ID: 36837481
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
    Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, Vij R, Strek ME, Chung JH.
    Ann Am Thorac Soc; 2019 May 31; 16(5):580-588. PubMed ID: 30653927
    [Abstract] [Full Text] [Related]

  • 14. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
    Lancet Respir Med; 2020 May 31; 8(5):453-460. PubMed ID: 32145830
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C, Cottin V.
    Curr Opin Pulm Med; 2022 Sep 01; 28(5):407-413. PubMed ID: 35938201
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.